Trials / Terminated
TerminatedNCT00670202
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
The Effect of Fasudil on Rho Kinase Activity in Patients Scheduled for Elective Carotid Endarterectomy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the causal relationship between Rho/Rho kinase overactivity and mechanisms of vascular dysfunction in patients with atherosclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fasudil Hydrochloride | Fasudil 40 mg three times a day x 14 days |
| DRUG | Placebo Oral Tablet | Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days |
Timeline
- Start date
- 2008-03-13
- Primary completion
- 2011-01-20
- Completion
- 2011-01-20
- First posted
- 2008-05-01
- Last updated
- 2017-03-29
- Results posted
- 2017-03-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00670202. Inclusion in this directory is not an endorsement.